Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Gamma Knife, its optimal use - a Letter.

British journal of neurosurgery·2026
Same author

The Reformation.

Progress in brain research·2024
Same author

Two surgical instruments.

Progress in brain research·2024
Same author

Cranial sutures.

Progress in brain research·2024
Same author

The meninges.

Progress in brain research·2024
Same author

The pericranium.

Progress in brain research·2024

Related Experiment Video

Updated: Oct 5, 2025

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.2K

High grade gliomas.

Jeremy C Ganz1

  • 1Department of Neurosurgery, Haukeland University Hospital, Bergen, Norway.

Progress in Brain Research
|January 25, 2022
PubMed
Summary
This summary is machine-generated.

Gamma Knife radiosurgery (GKNS) shows limited benefit for primary malignant glioma treatment. However, combining GKNS with bevacizumab may improve survival for younger patients with recurrent tumors under 4cm.

Keywords:
Anaplastic astrocytomaGlioblastoma multiformeNew brain tumor classificationRecurrent tumorSelection criteria

More Related Videos

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.1K
Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
12:25

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Published on: January 7, 2014

15.4K

Related Experiment Videos

Last Updated: Oct 5, 2025

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma
05:45

Author Spotlight: Enhanced Generation of Patient-Derived 3D Organoids for Glioblastoma and Glioma

Published on: January 19, 2024

2.2K
Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma
10:58

Transposon Mediated Integration of Plasmid DNA into the Subventricular Zone of Neonatal Mice to Generate Novel Models of Glioblastoma

Published on: February 22, 2015

13.1K
Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry
12:25

Optimization of High Grade Glioma Cell Culture from Surgical Specimens for Use in Clinically Relevant Animal Models and 3D Immunochemistry

Published on: January 7, 2014

15.4K

Area of Science:

  • Neurosurgery
  • Radiation Oncology
  • Oncology

Background:

  • Malignant gliomas are aggressive brain tumors with limited primary treatment options.
  • The role of Gamma Knife radiosurgery (GKNS) in glioma management is under investigation.

Purpose of the Study:

  • To evaluate the efficacy of GKNS in the primary and recurrent treatment of malignant gliomas.
  • To assess the potential survival benefits of combining GKNS with bevacizumab.

Main Methods:

  • Review of existing evidence on GKNS for malignant gliomas.
  • Analysis of outcomes in patients with recurrent tumors treated with GKNS and bevacizumab.

Main Results:

  • GKNS has minimal efficacy as a primary treatment for malignant gliomas.
  • Combined GKNS and bevacizumab therapy demonstrated potential to prolong overall survival in select patients with recurrent tumors (≤4cm, younger age).

Conclusions:

  • GKNS has a restricted role in malignant glioma management, particularly in primary settings.
  • Further research is necessary to define the optimal application of GKNS, especially in combination therapies for recurrent gliomas.